Elanco Animal Health (NYSE:ELAN) Price Target Raised to $30.00 at Leerink Partners

Elanco Animal Health (NYSE:ELAN) had its price objective lifted by Leerink Partners from $26.00 to $30.00 in a research report released on Tuesday,Benzinga reports. The brokerage currently has an outperform rating on the stock.

A number of other equities analysts have also recently issued reports on the stock. UBS Group increased their price objective on shares of Elanco Animal Health from $27.00 to $30.00 and gave the company a “buy” rating in a research note on Thursday, January 29th. Barclays initiated coverage on shares of Elanco Animal Health in a research note on Tuesday, December 9th. They issued an “overweight” rating and a $30.00 target price on the stock. KeyCorp restated an “overweight” rating on shares of Elanco Animal Health in a research note on Wednesday, December 10th. Piper Sandler raised Elanco Animal Health from a “neutral” rating to an “overweight” rating and lifted their price objective for the company from $24.00 to $30.00 in a report on Thursday, January 22nd. Finally, Weiss Ratings reissued a “sell (d+)” rating on shares of Elanco Animal Health in a report on Monday, December 29th. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $27.22.

Elanco Animal Health Stock Up 6.4%

ELAN stock opened at $26.34 on Tuesday. Elanco Animal Health has a twelve month low of $8.02 and a twelve month high of $26.87. The company has a quick ratio of 1.23, a current ratio of 2.40 and a debt-to-equity ratio of 0.59. The company has a market cap of $13.09 billion, a PE ratio of 439.11, a price-to-earnings-growth ratio of 3.69 and a beta of 1.87. The business’s 50-day simple moving average is $23.97 and its 200 day simple moving average is $21.62.

Elanco Animal Health (NYSE:ELAN) last announced its quarterly earnings data on Tuesday, February 24th. The company reported $0.13 EPS for the quarter, topping analysts’ consensus estimates of $0.11 by $0.02. Elanco Animal Health had a return on equity of 7.41% and a net margin of 0.78%.The company had revenue of $1.14 billion during the quarter, compared to the consensus estimate of $1.09 billion. During the same quarter last year, the company earned $0.14 EPS. The company’s quarterly revenue was up 12.2% on a year-over-year basis. Elanco Animal Health has set its Q1 2026 guidance at 0.330-0.36 EPS and its FY 2026 guidance at 1.000-1.060 EPS. On average, research analysts anticipate that Elanco Animal Health will post 0.91 earnings per share for the current year.

Insider Activity

In other Elanco Animal Health news, CEO Jeffrey N. Simmons bought 22,000 shares of Elanco Animal Health stock in a transaction dated Thursday, December 11th. The shares were acquired at an average cost of $21.75 per share, with a total value of $478,500.00. Following the acquisition, the chief executive officer directly owned 167,000 shares of the company’s stock, valued at $3,632,250. The trade was a 15.17% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CFO Robert M. Vanhimbergen purchased 6,950 shares of the firm’s stock in a transaction that occurred on Thursday, December 11th. The shares were acquired at an average price of $21.64 per share, for a total transaction of $150,398.00. Following the completion of the transaction, the chief financial officer owned 124,233 shares in the company, valued at $2,688,402.12. The trade was a 5.93% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Over the last three months, insiders have purchased 43,450 shares of company stock worth $937,883. 0.89% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of ELAN. NewEdge Advisors LLC lifted its stake in Elanco Animal Health by 133.7% in the fourth quarter. NewEdge Advisors LLC now owns 1,096 shares of the company’s stock valued at $25,000 after buying an additional 627 shares during the period. SJS Investment Consulting Inc. increased its stake in shares of Elanco Animal Health by 2,563.5% in the 3rd quarter. SJS Investment Consulting Inc. now owns 1,385 shares of the company’s stock valued at $28,000 after acquiring an additional 1,333 shares during the last quarter. Huntington National Bank raised its position in shares of Elanco Animal Health by 136.7% in the 3rd quarter. Huntington National Bank now owns 1,882 shares of the company’s stock valued at $38,000 after acquiring an additional 1,087 shares during the period. Root Financial Partners LLC boosted its stake in Elanco Animal Health by 50.7% during the 4th quarter. Root Financial Partners LLC now owns 1,759 shares of the company’s stock worth $40,000 after acquiring an additional 592 shares during the last quarter. Finally, Uniplan Investment Counsel Inc. acquired a new position in Elanco Animal Health during the fourth quarter valued at approximately $41,000. Institutional investors and hedge funds own 97.48% of the company’s stock.

Key Headlines Impacting Elanco Animal Health

Here are the key news stories impacting Elanco Animal Health this week:

• Positive Sentiment: Q4 beat on top- and bottom-line — Elanco reported adjusted EPS of $0.13 (vs. $0.11 est.) and revenue of $1.144B (above estimates), with revenue up ~12% year-over-year. Elanco Animal Health Reports Fourth Quarter and Full Year 2025 Results
• Positive Sentiment: Raised targets for innovation and product momentum — Elanco raised its 2026 innovation revenue target to $1.15B and highlighted delivery of the “Big 6” launches (including Befrena), supporting mid‑term growth expectations. Elanco Animal Health Reports Fourth Quarter and Full Year 2025 Results
• Positive Sentiment: Analyst upgrades/price target lifts — Leerink raised its price target to $30 with an outperform rating, adding buy-side support after the results. Leerink raises PT to $30 (Benzinga)
• Neutral Sentiment: FY‑2026 guidance roughly in line with Street — Elanco guided to adjusted EPS $1.00–$1.06 and revenue $4.95B–$5.02B (consensus ~ $1.03 EPS / $4.9B revenue), and Q1 EPS 0.33–0.36 (near consensus). That keeps 2026 growth narrative intact but leaves little upside surprise baked in. Elanco Sees Revenue Growth in 2026 (MarketWatch)
• Negative Sentiment: Margin pressure concerns weighed on sentiment — Several outlets flagged investor worry about near-term margin trends and adjusted EBITDA/margin trajectory, which capped upside despite the beats. That drove some intraday selling in parts of the tape. Elanco beats estimates but shares edge down on margin concerns (Investing.com)
• Negative Sentiment: GAAP loss and leverage remain watch points — The company reported a GAAP net loss and a net leverage ratio ~3.6x (targeting ~3.1–3.3x year‑end), which keeps balance‑sheet/credit risk and cash‑flow conversion on investors’ radar. Elanco Animal Health Reports Fourth Quarter and Full Year 2025 Results

About Elanco Animal Health

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.